Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Merck and : Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CEST

Release date- 02102017 - EAGAN, MN - Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera's novel phase 2 cancer immunotherapy.

These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI- EORTC will feature initial translational research from Biothera's ongoing phase 2 clinical study combining Imprime PGG and Merck's anti-PD-1 antibody, Keytruda, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.

About Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.

Contact:

David Walsh

Tel: 651-256-4606

Email: dwalsh@biothera.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
09/21MERCK FOLLOWS OPDIVOS SUIT, PRICES K : report
AQ
09/20MERCK : Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudi..
BU
09/20MERCK AND : Publishes Corporate Responsibility Report
PR
09/19ASTELLAS PHARMA : Announces Launch of Dafclir Tablets for the Treatment of Infec..
AQ
09/18DOW MOVERS : Dis, aapl
AQ
09/14MERCK AND : FDA Grants Priority Review to Merck's Application for KEYTRUDA Monot..
AQ
09/14MERCK AND COMPANY : Ex-dividend day for
FA
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13MERCK AND : ZERBAXA Met Primary Endpoints of Non-Inferiority Compared to Meropen..
AQ
09/13BIOCENTURY - MANAGEMENT TRACKS : Clearside, ImCheck
AQ
More news
News from SeekingAlpha
09/23The Dogs Of The Dow September Update By Dividend Dogcatcher 
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Sutro Biopharma Prepares Terms For $75 Million U.S. IPO 
09/21Key events next week - healthcare 
09/20European advisory group backs Merck's HIV meds Delstrigo and Pifeltro 
Financials ($)
Sales 2018 42 371 M
EBIT 2018 13 742 M
Net income 2018 7 016 M
Debt 2018 14 978 M
Yield 2018 2,74%
P/E ratio 2018 27,54
P/E ratio 2019 18,57
EV / Sales 2018 4,82x
EV / Sales 2019 4,57x
Capitalization 189 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 73,0 $
Spread / Average Target 2,7%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY26.36%189 092
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
AMGEN17.94%132 756